サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1493329

米国の顔用注射剤市場規模・シェア・動向分析レポート：製品別、用途別、最終用途別、地域別、セグメント予測、2024年～2030年

U.S. Facial Injectable Market Size, Share & Trends Analysis Report By Product (Botulinum Toxin Type A, HA), By Application (Facial Line Correction, Lip Augmentation), By End-use, By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 70 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
米国の顔用注射剤市場規模・シェア・動向分析レポート：製品別、用途別、最終用途別、地域別、セグメント予測、2024年～2030年
出版日: 2024年05月27日
発行: Grand View Research
ページ情報: 英文 70 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の顔用注射剤市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の顔用注射剤市場は2024年から2030年にかけて11.1％のCAGRを示し、2030年には80億2,000万米ドルに達すると予測されています。

美容施術の受け入れ拡大や老人人口の増加が市場成長を促進する主な要因の一つです。

米国の老年人口の増加は、低侵襲外科処置の開発に対する需要を高めています。顔用注射剤は、いくつかの美容外科処置の代替手段を提供します。さらに、これらの処置は、より少ない痛み、より少ない外傷、より少ない出血、より速い回復などのいくつかの利点を提供します。加えて、アレルギーリスクの少ない需要に特化したソリューションの開拓に注力する市場プレイヤーの増加は、市場の成長に大きく貢献しています。

顔の外見への注目の高まりに起因する美容整形に対する意識の高まりは、市場の成長をさらに後押ししています。さらに、患者のさまざまな需要に対応する顔用注射剤が利用可能になったことで、患者のニーズに応じてさまざまな年齢層での需要が増加しています。例えば、米国形成外科学会（The American Society of Plastic Surgeons）の2022年形成外科統計報告書によると、2022年の30歳から39歳、40歳から54歳の年齢層における神経調節剤注入手術の件数は、2019年から70％、74％同時に増加しています。同様に、2022年の30～39歳と40～54歳の年齢層におけるHAフィラーの施術数は、2019年から69％と70％同時に増加しています。このように、異なる年齢層における顔用注入剤の需要の増加は、予測期間中の市場成長を促進すると予想されます。

米国の顔用注射剤市場レポートハイライト

  • A型ボツリヌス毒素は、シワ、目尻のシワ、側口角など幅広い治療が可能であるため、2023年には55％以上のシェアを獲得し、製品タイプを支配しました。
  • HA分野は、ヒアルロン酸フィラーの開発に注力する市場プレイヤーの増加により、予測期間中に最も急速な成長が見込まれます。低侵襲処置に対する需要の増加と美容処置の急増が市場成長を牽引しています。
  • 米国の顔用注入剤市場に参入している市場プレーヤーには、AbbVie, Inc.、REVANCE AESTHETICS、Merz North America, Inc.、Galderma Laboratories, L.P.、Suneva Medical Inc.、Cytophil, Inc.、Prollenium Medical Technologiesなどがあります。
  • 2023年5月、エボルス社は開発中の5種類の皮膚充填剤の販売代理店契約をシマテーゼ社と締結したと発表しました。この一歩は、同社が製品ポートフォリオを拡大し、多製品を扱う美容企業になるための一歩を踏み出す上で大きな助けとなった。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の顔用注射剤市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 米国の顔用注射剤市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の顔用注射剤市場：製品推定・動向分析

  • 製品市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 米国の顔用注射剤市場（製品別）の見通し
  • 2018年から2030年までの市場規模と予測および動向分析
  • コラーゲン
  • ボツリヌス毒タイプA
  • HA
  • CaHA
  • PLLA
  • その他

第5章 米国の顔用注射剤市場：用途の推定・動向分析

  • 用途市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 米国の顔用注射剤市場（用途別）の見通し
  • 2018年から2030年までの市場規模と予測および動向分析
  • 輪郭修正
  • 口唇拡大
  • フェイスリフト
  • ニキビ跡治療
  • 脂肪萎縮治療
  • その他

第6章 米国の顔用注射剤市場：最終用途の推定・動向分析

  • 最終用途市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 最終用途別米国顔用注射剤市場展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • メディスパ
  • 皮膚科クリニック
  • 病院

第7章 米国の顔用注射剤市場：地域推定・動向分析

  • 地域別市場シェア、2023年および2030年
  • 地域別米国顔用注射剤市場展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 西部
  • 中西部
  • 北東部
  • 南西部
  • 南東部

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
  • 企業プロファイル
    • AbbVie, Inc.
    • REVANCE AESTHETICS
    • Merz North America, Inc.
    • Galderma Laboratories, LP
    • Suneva Medical Inc.
    • Cytophil, Inc
    • Prollenium Medical Technologies.
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. facial injectable market, by product, 2018 - 2030 (USD Million)
  • Table 4 U.S. facial injectable market, by application, 2018 - 2030 (USD Million)
  • Table 5 U.S. facial injectable market, by end-use, 2018 - 2030 (USD Million)
  • Table 6 U.S. facial injectable market, by region, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. facial injectable market: market outlook
  • Fig. 9 U.S. facial injectable competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. facial injectable market driver impact
  • Fig. 14 U.S. facial injectable market restraint impact
  • Fig. 15 U.S. facial injectable market: Product movement analysis
  • Fig. 16 U.S. facial injectable market: Product outlook and key takeaways
  • Fig. 17 Collagen & PMMA microspheres market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Botulinum toxin type A market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 HA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 CaHA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 PLLA market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. facial injectable market: Application movement Analysis
  • Fig. 24 U.S. facial injectable market: Application outlook and key takeaways
  • Fig. 25 Facial line correction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Lip augmentation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Face lift market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Acne scar treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Lipoatrophy treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. facial injectable market: End-use movement analysis
  • Fig. 32 U.S. facial injectable market: End-use outlook and key takeaways
  • Fig. 33 MedSpa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Dermatology clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. facial injectable market: Regional movement analysis
  • Fig. 37 U.S. facial injectable market: Regional outlook and key takeaways
  • Fig. 38 West market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-284-1

U.S. Facial Injectable Market Growth & Trends:

The U.S. facial injectable market is anticipated to reach USD 8.02 billion by 2030, exhibiting a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing acceptance of aesthetic procedures and the increasing geriatric population are some of the major factors driving the market growth.

The increasing geriatric population of the U.S. is increasing the demand for the development of minimally invasive surgical procedures. Facial injectable offer an alternative to several aesthetic surgical procedures. Moreover, these procedures offer several advantages, such as less pain, less trauma, lesser blood loss, and faster recovery. In addition, the increasing focus of market players on developing demand-specific solutions with lesser allergy risk significantly contributes to the market growth.

The increasing awareness about aesthetic procedures owing to the rising focus on facial appearance further drives the market growth. Moreover, the availability of facial injectable to address different demands of patients has increased their demand in different age groups as per their needs. For instance, according to the 2022 Plastic Surgery Statistics Report of The American Society of Plastic Surgeons, the number of neuromodulator injection procedures in the age group of 30 to 39 and 40 to 54 in 2022 has increased by 70% and 74% from 2019 simultaneously. Similarly, the number of HA filler procedures in the age group of 30 to 39 and 40 to 54 in 2022 has increased by 69% and 70% from 2019 simultaneously. This increasing demand for facial injectable in different age groups is expected to drive market growth over the forecast period.

U.S. Facial Injectable Market Report Highlights:

  • Botulinum toxin type A dominated the product segment with a share of over 55% share in 2023 owing to its wide treatment, such as wrinkles, glabellar lines, lateral canthus, and others.
  • The HA segment is expected to witness the fastest growth over the forecast period owing to the increasing focus of market players on developing hyaluronic fillers. The increasing demand for minimally invasive procedures and the surge in aesthetic procedures are driving the market growth.
  • Some of the market players operating in the U.S. facial injectable market include AbbVie, Inc., REVANCE AESTHETICS, Merz North America, Inc., Galderma Laboratories, L.P., Suneva Medical Inc., Cytophil, Inc, and Prollenium Medical Technologies.
  • In May 2023, Evolus, Inc. announced that the company had entered into an agreement with Symatese to be the distributor of five under-development derma fillers. This step significantly helped the company in expanding its product portfolio and taking a step towards becoming a multi-product aesthetic company.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End-use
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Application outlook
    • 2.2.3. End-use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Facial Injectable Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing geriatric population
      • 3.2.1.2. Rising awareness of aesthetic procedures
      • 3.2.1.3. Increasing availability of innovative products
      • 3.2.1.4. Rise in the number of aesthetic procedures performed
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Threat of side effects
  • 3.3. U.S. Facial Injectable Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Facial Injectable Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Facial Injectable Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Collagen & PMMA microspheres
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Botulinum toxin type A
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. HA
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. CaHA
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. PLLA
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Others
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Facial Injectable Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Facial Injectable Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Facial line correction
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Lip augmentation
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Face lift
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Acne scar treatment
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Lipoatrophy treatment
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Others
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Facial Injectable Market: End-use Estimates & Trend Analysis

  • 6.1. End-use Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Facial Injectable Market by End-use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. MedSpa
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Dermatology clinics
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Hospitals
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Facial Injectable Market: Region Estimates & Trend Analysis

  • 7.1. Regional Market Share, 2023 & 2030
  • 7.2. U.S. Facial Injectable Market by Region Outlook
  • 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
    • 7.3.1. West
      • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.3.2. Midwest
      • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Northeast
      • 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Southwest
      • 7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.5. Southeast
      • 7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. AbbVie, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. REVANCE AESTHETICS
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Merz North America, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Galderma Laboratories, L.P.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Suneva Medical Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Cytophil, Inc
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Prollenium Medical Technologies.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives